Key result
Adriamycin exposure was associated with severe cardiomyopathy with congestive heart failure in 16% of children, compared to 3% of those receiving daunomycin.
Why the study?
What is the incidence of severe cardiomyopathy in children receiving cumulative doses of over 500 mg/m2 of adriamycin or daunomycin?
Observational (n=110)
What is the incidence of severe cardiomyopathy in children receiving cumulative doses of over 500 mg/m2 of adriamycin or daunomycin?
High cumulative doses (>500 mg/m2) of adriamycin and daunomycin in children are associated with severe cardiomyopathy, with a higher incidence observed with adriamycin and concurrent cardiac radiation.
Answers are grounded in this paper and cite their sources.
May warrant cardiac surveillance for high-dose adriamycin in children; leaves open randomized comparisons with daunomycin.
Eight (16%) of 50 children receiving adriamycin and 2 (3%) of 60 receiving daunomycin had severe cardiomyopathy with congestive heart failure. All 110 patients received cumulative doses of over 500 mg/m2. The incidence was significantly higher in those who also had incidental cardiac radiation. The electrocardiogram, with few exceptions, provided the first indication of cardiac abnormality. There were no deaths from heart failure. Two had thromboembolic episodes. Recommendations are discussed.
No takes yet. Share an insight, caveat, or question.
Gilladoga et al. (1976) conducted an observational in Cardiotoxicity (n=110). Adriamycin vs. Daunomycin was evaluated on severe cardiomyopathy with congestive heart failure. Adriamycin exposure was associated with severe cardiomyopathy with congestive heart failure in 16% of children, compared to 3% of those receiving daunomycin.
Synapse has enriched 10 related papers. Consider them for comparative context: